If the detector is incapable of detecting the responses of sample matrix , how we could say the sample matrix is eluting at the same retention time of main peak of interest?
You have an answer in your question itself, If the detector is incapable of detecting such components,that particular component will not get detected even if its merge with principle peak so we will only get the area of principle peak
U can use validated drug substance method or pharmacopeal methods for assay and RS as orthogonal procedure
Can you just make playlist of videos for better understanding?
If the detector is incapable of detecting the responses of sample matrix , how we could say the sample matrix is eluting at the same retention time of main peak of interest?
Exactly..!!
You have an answer in your question itself, If the detector is incapable of detecting such components,that particular component will not get detected even if its merge with principle peak so we will only get the area of principle peak
Sir please do if possible a detailed video on Q14 Guideline.
Very informative
Make playlist sir for continuity
Sir please explain how to calculate peak purity.
😊😊
😊😊😊😊😊
Please give link for draft guidelines
database.ich.org/sites/default/files/ICH_Q2-R2_Document_Step2_Guideline_2022_0324.pdf
Dont show plz dont come in front of me